Brokerages Expect Clearside Biomedical Inc (CLSD) to Post -$0.56 EPS

Brokerages expect that Clearside Biomedical Inc (NASDAQ:CLSD) will announce ($0.56) earnings per share (EPS) for the current quarter, Zacks reports. Zero analysts have made estimates for Clearside Biomedical’s earnings, with the lowest EPS estimate coming in at ($0.76) and the highest estimate coming in at ($0.32). Clearside Biomedical posted earnings per share of ($0.65) in the same quarter last year, which indicates a positive year over year growth rate of 13.8%. The firm is expected to report its next earnings results on Wednesday, March 13th.

On average, analysts expect that Clearside Biomedical will report full year earnings of ($2.57) per share for the current year, with EPS estimates ranging from ($2.77) to ($2.33). For the next fiscal year, analysts forecast that the firm will report earnings of ($1.31) per share, with EPS estimates ranging from ($1.50) to ($1.04). Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side research firms that cover Clearside Biomedical.

Clearside Biomedical (NASDAQ:CLSD) last released its earnings results on Thursday, November 8th. The company reported ($0.75) EPS for the quarter, missing analysts’ consensus estimates of ($0.63) by ($0.12).

A number of research analysts have recently issued reports on the company. Zacks Investment Research raised Clearside Biomedical from a “hold” rating to a “buy” rating and set a $1.25 price target on the stock in a report on Thursday, January 3rd. Cowen downgraded Clearside Biomedical from an “outperform” rating to a “market perform” rating in a report on Monday, November 5th. JPMorgan Chase & Co. downgraded Clearside Biomedical from an “overweight” rating to an “underweight” rating in a report on Monday, November 5th. Laidlaw set a $5.00 price target on Clearside Biomedical and gave the company a “buy” rating in a report on Tuesday, November 6th. Finally, Janney Montgomery Scott set a $4.00 price target on Clearside Biomedical and gave the company a “buy” rating in a report on Tuesday, November 6th. Two investment analysts have rated the stock with a sell rating, three have issued a hold rating and six have issued a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average target price of $11.28.

Hedge funds have recently bought and sold shares of the business. Virtu Financial LLC bought a new position in Clearside Biomedical in the fourth quarter valued at about $57,000. Voya Investment Management LLC bought a new position in shares of Clearside Biomedical in the second quarter worth about $123,000. Bank of America Corp DE raised its stake in shares of Clearside Biomedical by 915.6% in the second quarter. Bank of America Corp DE now owns 16,574 shares of the company’s stock worth $177,000 after buying an additional 14,942 shares during the period. Trexquant Investment LP bought a new position in shares of Clearside Biomedical in the third quarter worth about $188,000. Finally, Engineers Gate Manager LP bought a new position in shares of Clearside Biomedical in the third quarter worth about $202,000. 57.94% of the stock is currently owned by institutional investors.

Shares of NASDAQ:CLSD traded up $0.03 during midday trading on Tuesday, reaching $1.16. 268,521 shares of the company’s stock traded hands, compared to its average volume of 679,640. The company has a quick ratio of 4.59, a current ratio of 4.59 and a debt-to-equity ratio of 0.22. Clearside Biomedical has a one year low of $0.99 and a one year high of $15.33.

Clearside Biomedical Company Profile

Clearside Biomedical, Inc, a late-stage clinical biopharmaceutical company, develops pharmacological therapies to treat blinding diseases of the eye. It is developing suprachoroidal injection of CLS-TA, a proprietary preservative-free formulation of the corticosteroid triamcinolone acetonide, which is in Phase III clinical trial for the treatment of macular edema associated with non-infectious uveitis; suprachoroidal injection of CLS-TA and a concomitant intravitreal injection of Eylea, an inhibitor of vascular endothelial growth factor that is in Phase III clinical trial to treat macular edema associated with retinal vein occlusion; and suprachoroidal injection of CLS-TA alone or together with intravitreal injection of Eylea that is in phase II clinical trial for diabetic macular edema.

Featured Article: Compound Interest

Get a free copy of the Zacks research report on Clearside Biomedical (CLSD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Clearside Biomedical (NASDAQ:CLSD)

Receive News & Ratings for Clearside Biomedical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clearside Biomedical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply